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Long intergenic non-coding RNA 
expression signature in human 
breast cancer
Yanfeng Zhang1,*,†, Erin K. Wagner2,*, Xingyi Guo1, Isaac May3, Qiuyin Cai1, Wei Zheng1, 
Chunyan He2,4 & Jirong Long1
Breast cancer is a complex disease, characterized by gene deregulation. There is less systematic 
investigation of the capacity of long intergenic non-coding RNAs (lincRNAs) as biomarkers associated 
with breast cancer pathogenesis or several clinicopathological variables including receptor status and 
patient survival. We designed a two-stage study, including 1,000 breast tumor RNA-seq data from 
The Cancer Genome Atlas (TCGA) as the discovery stage, and RNA-seq data of matched tumor and 
adjacent normal tissue from 50 breast cancer patients as well as 23 normal breast tissue from healthy 
women as the replication stage. We identified 83 lincRNAs showing the significant expression changes 
in breast tumors with a false discovery rate (FDR) < 1% in the discovery dataset. Thirty-seven out of 
the 83 were validated in the replication dataset. Integrative genomic analyses suggested that the 
aberrant expression of these 37 lincRNAs was probably related with the expression alteration of several 
transcription factors (TFs). We observed a differential co-expression pattern between lincRNAs and their 
neighboring genes. We found that the expression levels of one lincRNA (RP5-1198O20 with Ensembl ID 
ENSG00000230615) were associated with breast cancer survival with P < 0.05. Our study identifies a set 
of aberrantly expressed lincRNAs in breast cancer.
The advances in high-throughput sequencing technologies provide a systematic landscape in the complexity 
of transcriptome, especially the discovery of a wealth of long non-coding transcripts1,2. This phenomenon is 
referred to as pervasive transcription3, albeit some transcripts are probably the byproduct of the transcription 
noise4. Characterized as transcription from the intergenic regions, lincRNAs are specific types of long non-coding 
RNAs (lncRNAs), ranging in length from 200 nt to > 100 kb5. Biochemically, many lincRNAs harbor mRNA-like 
features, such as the poly-adenosine (polyA+ ) tail and splicing6, enabling them to be detectable by polyA+ 
RNA-sequencing (RNA-seq) method. Functionally, there is mounting evidence that lincRNAs may act as modu-
lar scaffolds to recruit other active or repressive regulators7, resulting in widespread roles in imprinting control8, 
chromosome remodeling9, pluripotency and differentiation10, immune responses11 and cancer progression12. 
Many lincRNAs are expressed in high tissue or cell specificity10, serving lincRNA molecules as potential disease 
biomarkers.
Recently, the Cancer Genome Atlas (TCGA) has revealed that the aberrant expression of hundreds of 
protein-coding genes and tens of microRNAs are associated with breast cancer development, progression, metas-
tasis13–16 and subtypes17,18. One large-scale study also reported hundreds of lincRNAs showing expression changes 
in breast cancer19, but this study has a lack of replication and comprehensive analyses. To further use lincRNAs 
as robust biomarkers, we performed an integrative analysis on RNA-seq data from approximately 1,000 breast 
tumors from the TCGA and an independent RNA-seq dataset of 50 pairs of matched tumors and adjacent normal 
tissues from breast cancer patients as well as 23 normal breast tissues from healthy women.
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Results
Data summary. In the discovery stage, RNA-seq data for 85 pairs of breast tumors and adjacent normal 
tissues were collected, along with 830 primary breast tumors available from TCGA. In the replication stage, RNA-
seq data from paired tumor and adjacent normal tissues from 50 breast cancer patients and normal breast tissue 
from 23 healthy women were included. Overall, the study subjects had similar clinical characteristics between the 
two stages (Table 1).
Also included in the present study were Genome-wide protein-DNA interaction data using chromatin immu-
noprecipitation followed by sequencing (ChIP-seq) for 26 transcription factors (TFs) in MCF-7 cell lines from 
the ENCODE project, and two independent ChIP-seq datasets for transcription factor ERα each with replicated 
experiments in the MCF-7 cells20,21, as well as RNA-seq data across 14 breast cancer cell lines (Table S1).
Global changes of the lincRNA species in breast cancer. Our transcriptomic analyses focused on the 
lincRNA species, a specific type of lncRNAs. First, we investigated the lincRNA expression profile in 85 paired 
samples of primary breast tumor tissue and adjacent normal tissue from TCGA. After stringent filtering (see 
Methods), we totally identified 2,171 lincRNAs expressed in at least one sample. As expected, most lincRNAs 
expressed at low levels and sparsely expressed in < 10% of all samples (Figure S1). Similar observations were 
also reported elsewhere22–24. For subsequent analysis, we focused on 584 lincRNAs that expressed in at least 20% 
of samples. Compared with the matched adjacent normal tissues, we observed that these lincRNAs showed a 
global decreased expression profile in breast tumors (Figure S2). The similar trend has been reported for small 
non-coding RNAs in multiple cancer types25,26. Specifically, among these 584 lincRNAs, 83 were significantly 
differential expression (DE) with a permutation-based FDR < 1% (Fig. 1A). Among them, 60 lincRNAs displayed 
down-regulation in breast tumor tissues.
Validation of lincRNA expression in an independent study. To validate the DE lincRNAs identified 
in TCGA, we generated an independent RNA-seq dataset from 50 pairs of matched tumor and adjacent nor-
mal samples from breast cancer patients and 23 normal breast tissues from healthy women in the replication 
study. Among the 83 DE lincRNAs, 66 lincRNAs (80%) showed consistent expression change direction (Fig. 1B). 
Specifically, 37 lincRNAs (45%) were replicated with absolute log2-FC ≥ 1 and P < 0.05 in the 50 pairs of matched 
tumor and adjacent normal breast tissues in replication stage (Table 2). Over 80% of them also showed significant 
expression difference in the tumors compared to normal breast tissues in the validation stage (Table 2). When we 
relaxed the cutoff to absolute log2-FC ≥ 0.585 and P < 0.05 in the replication dataset (Table S2), 47 DE lincRNAs 
(57%) could be replicated in our independent study, which is consistent with the previous report19.
We further examined the expression profiling of the 37 replicated lincRNAs in the remaining 830 breast tumor 
tissues samples without matched normal tissues from the TCGA dataset. The expression patterns of these 37 lin-
cRNAs in the 830 tumor samples were very similar to those in 85 normal-paired breast tumor samples, but very 
different from those in adjacent normal breast tissue samples in the discovery stage (Fig. 1C). Principal compo-
nent analysis (PCA) based on these 37 lincRNAs also showed that all breast tumor samples are clustered together, 
but separated from the adjacent normal tissues (with a few exceptions) (Fig. 1D). In addition, we also checked 
the expression levels of these 37 lincRNAs across 14 breast cancer cell lines that are commonly used in the lab 
(Table S3). Most of these 37 lincRNAs were expressed in at least one common breast cancer cell line, making these 






normal tissues Healthy Women
No. of samples 85 830 50 23
Age (yr ± s.d.) 57.2 ± 15.4 58.4 ± 12.9 51.7 ± 10.9 52.0 ± 11.3
Ethnicity
 White 79 (92.9%) 588 (70.8%) 39 (78%) 18 (78%)
 Asian 1 (1.2%) 56 (6.8%) 0 0
 Black 5 (5.9%) 79 (9.5%) 11 (22%) 5 (22%)
 Unknown 0 107 (12.9%) 0 0
ER status
 ER+ 67 (78.9%) 597 (71.9%) 40 (80%) NA
 ER− 15 (17.6%) 181 (21.8%) 10 (20%) NA
 Unknown 3 (3.5%) 52 (6.3%) 0 NA
Stage
 0-I 16 (18.8%) 135 (16.2%) 2 (4%) NA
 II 46 (54.1%) 469 (56.5%) 14 (28%) NA
 III 20 (23.5%) 179 (21.6%) 6 (12%) NA
 IV 2 (2.4%) 13 (1.6%) 1 (2%) NA
 Unknown 1 (1.2%) 34 (4.1%) 27 (54%) NA
Table 1.  Clinical characteristic of study subjects in this study. aBRCA (breast invasive carcinoma) with 
matched adjacent normal tissues. bBRCA without matched adjacent normal tissues.
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cell lines as possible in vitro model to study lincRNAs. Altogether, these results suggested that these 37 lincRNAs 
showed aberrant expression in breast tumors.
Association of LincRNAs with transcription factors. We then integrated 26 known TFs ChIP-seq data 
in MCF-7 cells, an ER+ breast cancer cell line from the ENCODE project (Table S4), to investigate whether 
and to what extent the 37 differentially expressed lincRNAs are functionally related to TFs. We constructed a 
lincRNA-TF bipartite network (see Methods), which consisted of 45 nodes and 101 edges (Fig. 2A). We found 
Figure 1. Expression differences of lincRNAs between human breast cancer and normal tissues. (A) Heatmap of 
83 differentially expressed lincRNAs in 85 pair-matched breast cancer samples. Red and green bars denote 85 breast 
cancer specimens and adjacent normal tissues from TCGA, respectively. Colors ranging from blue to red represent 
the relative expression levels (Z-score) of lincRNAs. (B) Dot plot of the Log2-transformed FC for 83 lincRNAs 
between 50 paired breast tumor and adjacent normal tissues (Tumor− Adjacent), and between 50 breast tumors 
and 23 normal tissues from healthy women (Tumor− Normal) as validation (X-axis) versus that from TCGA breast 
cancer patients (Y-axis). (C) Heatmap of 37 differentially expressed and replicated lincRNAs in 830 unmatched 
tumors (blue bar) in combined with 85 pairs of tumors (red bar) and adjacent normal tissues (green bar). Values 
range in color from blue to red, meaning the relative expression levels. (D) PCA of 85 paired breast cancer and 
adjacent normal samples (85 BRCA and 85 Adjacent) and 830 unpaired breast cancer samples (830 BRCA) based on 
37 differentially expressed lincRNAs.
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that 20 (54.1%) lincRNAs were bound by at least one TF, and 25 of the 26 TFs regulated at least one lincRNA. 
Especially, each of the eight key TFs, including GATA3, RAD21, MYC, CTCF, MAX, E2F1, CEBPB and RNA 
polymerase II, binds ≥ 5 lincRNAs. Among them, 11 TFs exhibited a significant differential expression (abso-
lute log2-FC ≥ 0.585, BH-adjusted P < 0.01) in breast cancer tissues compared with adjacent normal tissues 
(Fig. 2B). We also found that several over-expressed lincRNAs may be related to these key TFs. For example, 
two lincRNA genes (RP11-279F6 with Ensemble ID ENSG00000245750 and GATA3-AS1 with Ensemble ID 
ENSG00000197308) had DNA binding peaks by 16 and 20 TFs, respectively. Specifically, all three over-expressed 
key regulators in breast tumors, GATA3, E2F1 and RAD21, showed connection with these two lincRNAs 
(Fig. 2C,D). These results suggest that the expression alteration of lincRNAs in breast cancer is probably func-
tionally associated by one or multiple TFs in a complex way.
Co-expression of lincRNAs with nearby protein-coding genes. Several studies have reported that 
lincRNAs show an expression correlation with their neighboring protein-coding genes in normal tissues/cells5,27. 
We examined whether 37 DE lincRNAs could also exhibit the differential co-expression profile with the adjacent 
genes in breast cancer development. We classified these 37 lincRNA/mRNA pairs into three types: head-head 
Ensembl ID Symbol
Discovery stagea Replication Stageb Replication Stagec
Log2-FCd P Log2-FCd P Log2-FCd P
ENSG00000261039 RP11-417E7 7.04 1.47E-08 3.49 2.42E-03 7.11 6.45E-05
ENSG00000230838 AC093850 5.84 6.87E-08 9.72 1.19E-10 15.03 1.42E-11
ENSG00000224577 AC017048 3.26 4.31E-05 2.17 2.69E-02 1.03 4.56E-01
ENSG00000253364 RP11-731F5 2.52 4.88E-03 9.31 1.78E-09 13.17 1.16E-08
ENSG00000197308 GATA3-AS1 2.49 2.08E-05 8.27 6.36E-07 5.58 1.43E-02
ENSG00000259093 RP11-1112J20 2.20 6.87E-08 2.02 8.65E-07 2.78 4.02E-06
ENSG00000230615 RP5-1198O20 1.72 2.80E-04 6.53 1.75E-13 7.58 3.50E-09
ENSG00000253161 RP11-150O12 1.68 1.00E-03 4.61 4.12E-05 5.54 9.67E-04
ENSG00000245750 RP11-279F6 1.57 1.17E-03 4.96 1.63E-04 6.07 1.47E-03
ENSG00000214548 MEG3 − 1.17 2.47E-07 − 2.35 1.15E-07 − 0.75 2.18E-01
ENSG00000237697 LINC00312 − 1.18 9.13E-03 − 3.10 1.24E-04 0.41 7.27E-01
ENSG00000267519 CTD-3252C9 − 1.48 6.89E-11 − 1.01 4.12E-05 1.33 2.00E-05
ENSG00000267272 RP5-1052I5 − 1.56 2.64E-05 − 3.02 2.65E-04 − 2.37 3.67E-02
ENSG00000255455 RP11-890B15 − 1.62 1.28E-04 − 1.59 3.60E-04 − 1.35 3.52E-02
ENSG00000234076 TPRG1-AS1 − 1.74 3.52E-03 − 1.93 1.12E-03 − 3.37 2.06E-05
ENSG00000262728 AC123768 − 1.82 4.90E-08 − 1.58 1.27E-02 − 3.01 2.80E-04
ENSG00000269930 RP11-932O9 − 1.85 9.95E-07 − 1.82 8.56E-05 − 1.74 7.45E-03
ENSG00000260025 RP11-490M8 − 2.15 1.10E-06 − 1.99 1.18E-02 − 2.78 6.05E-03
ENSG00000260807 RP11-161M6 − 2.24 1.64E-06 − 1.96 4.49E-02 − 5.65 1.34E-05
ENSG00000231246 RP5-965F6 − 2.32 4.87E-07 − 3.42 5.22E-03 − 2.94 7.71E-02
ENSG00000266176 RP11-855A2 − 2.39 9.44E-04 − 4.16 9.90E-05 0.16 9.21E-01
ENSG00000260693 AC026150 − 2.44 1.08E-06 − 1.81 3.04E-04 − 1.19 8.99E-02
ENSG00000223477 LINC00842 − 2.46 8.86E-08 − 2.93 7.21E-04 − 5.50 1.07E-06
ENSG00000182021 RP11-381O7 − 2.57 2.33E-05 − 3.26 1.17E-06 − 3.67 8.14E-05
ENSG00000258498 DIO3OS − 2.68 1.01E-04 − 3.34 2.49E-05 − 3.76 9.62E-05
ENSG00000269936 MIR145 − 2.70 9.87E-13 − 1.34 5.52E-04 − 1.61 1.80E-03
ENSG00000229645 LINC00341 − 2.77 6.89E-11 − 3.89 7.12E-06 − 2.82 1.50E-02
ENSG00000261064 RP11-1000B6 − 2.79 9.95E-07 − 1.33 7.23E-03 − 1.77 6.81E-03
ENSG00000229108 AC005550 − 2.81 2.28E-05 − 4.31 4.11E-04 − 6.34 7.85E-05
ENSG00000267194 RP1-193H18 − 2.81 2.97E-06 − 2.32 1.43E-03 − 3.05 7.26E-04
ENSG00000260124 RP4-791K14 − 2.84 8.18E-06 − 1.84 8.56E-06 − 2.32 4.72E-05
ENSG00000224307 RP11-344B5 − 3.10 7.24E-04 − 2.07 2.87E-03 − 1.88 3.44E-02
ENSG00000178947 LINC00086 − 3.23 1.94E-09 − 1.59 2.60E-02 − 2.66 5.14E-03
ENSG00000259070 LINC00639 − 3.45 2.88E-07 − 2.30 8.87E-04 − 3.48 1.40E-04
ENSG00000271239 RP11-238F2 − 3.67 3.37E-06 − 3.19 3.08E-02 − 3.86 5.24E-02
ENSG00000262179 RP1-302G2 − 4.26 6.95E-07 − 5.21 3.39E-06 − 4.74 1.56E-03
ENSG00000246430 RP11-16M8 − 5.25 2.61E-06 − 6.36 4.27E-09 − 3.19 3.97E-02
Table 2.  Expression alteration of 37 lincRNAs in discovery and replication stages. aThe discovery stage from 
TCGA. b,cThe replication stage from an independent study; bcomparison between paired tumor and adjacent 
normal breast tissue from cancer patients; ccomparison between tumor and normal breast tissue from healthy 
controls. dLog2-FC denotes log2-transformed fold change between breast tumor and non-tumor samples.
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(H2H), head-tail (H2T) and tail-tail (T2T) based on the paired transcriptional orientation (Fig. 3A). We observed 
a coordinated expression change (r2 = 0.25, P = 1.0 × 10−4) between lincRNAs and their neighbor mRNAs via 
a comparison of 85 paired breast tumor and adjacent normal breast tissues (Fig. 3A and B). We detected 14 
(37.8%) lincRNA/mRNA pairs with the H2H type, which shows marginally significant over-representation 
Figure 2. LincRNAs link to the regulation by transcription factors. (A) LincRNA-transcription factors (TFs) 
bipartite network. Each node with size scaled by its degree (the number of directly linked nodes) denotes one 
TF (yellow hexagon) or lincRNA (circle). Each edge represents the regulation of lincRNAs by TFs. Red and 
green circles represent the over-expressed and down-expressed lincRNAs in breast cancer samples, respectively. 
(B) Volcano plot of the log2-transformed fold change between breast cancer and adjacent normal tissues 
(X-axis, n = 85 pairs) versus –log10-transformed BH adjusted P value (Y-axis) for TFs (n = 26). The marked TFs 
show significantly differential expression in breast cancers relative to adjacent normal tissues. (C,D) Examples 
of two lincRNA genes (RP11-279F6 with Ensemble ID ENSG00000245750 and GATA3-AS1 with Ensemble ID 
ENSG00000197308) regulated by multiple TFs.
www.nature.com/scientificreports/
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(p = 0.06, one-sided Binomial test) relative to the global distribution. Similar results were observed when 
we analyzed 83 initially detected DE lincRNAs (Figure S3). Taking the H2H pair of GATA3-AS1 (Ensembl 
Figure 3. Co-expression differences between lincRNAs and neighboring mRNAs. (A) Plot of log2-
transformed FC between 85 paired breast cancers for 37 lincRNAs (Y-axis) versus nearby mRNAs (X-axis). 
H2H, H2T and T2T represent the head-to-head, head-to-tail and tail-to-tail orientation between lincRNA 
and neighboring mRNAs, respectively (top panel). (B) Distribution of Spearman correlation coefficient 
from 85 adjacent normal tissues for lincRNA-neighboring pairs (blue) and lincRNA-non-neighboring pairs 
(pink). Functional enrichment and remarkable correlated protein-coding genes associated with lincRNA 
ENSG00000261039 (C,D) and ENSG00000230838 (E,F).
www.nature.com/scientificreports/
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ID ENSG00000197308) and its adjacent (aparting from 1220 bp) protein-coding gene GATA3 as an example 
(Figure S4), the correlation coefficient between these two genes was 0.54 with P = 6.7 × 10−5. These observations 
are consistent with the previous reports that both GATA3-AS1 and GATA3 are co-expressed in mouse and human 
TH2 cells28,29. Altogether, the lincRNAs divergently transcribed with protein-coding genes are more likely to show 
the differentially co-expression profiles.
To further determine the uniqueness of the differential co-expression observation of lincRNA-mRNA adja-
cent pairs, we characterized the co-expression patterns of non-neighboring lincRNA-mRNA pairs and randomly 
shuffled lincRNA-mRNA pairs using the same 85 pairs of breast cancer/adjacent normal tissue in discovery stage 
(see Methods). As expected, there were no co-expression changes for the random pairs (Figure S5). In addition, 
the neighboring lincRNA-mRNA pairs showed a higher Spearman’s rank correlation coefficient than those of 
non-neighboring lincRNA-mRNA pairs (Fig. 3B).
Functional Prediction of lincRNAs. To date, thousands of lincRNAs have been annotated, while the bio-
logical functions are unclear for most of them. Based on the Refseq genes showing strong co-expression relation-
ship with lincRNAs, a method commonly used for functional prediction of unknown genes30,31, we predicted the 
biological functions for these 37 lincRNAs (see Methods). Enrichment analysis of GO terms and KEGG pathways 
showed that these down-regulated lincRNAs might be associated with transcriptional regulation, RNA process-
ing and translational elongation processes, etc. In contrast, the up-regulated lincRNAs probably participate in 
cancer cell migration and proliferation, including cell adhesion, regulation of epithelial cell proliferation and 
regulation of cell cycle (Table S5). For example, two over-expressed lincRNAs (RP11-417E7 with Ensemble ID 
ENSG00000261039 and AC093850 with Ensemble ID ENSG00000230838) showed over-expression in both the 
discovery and the replication stage. These two lincRNAs may be involved in the ECM-receptor interaction and 
cell adhesion, TGFβ signaling pathway and others (Fig. 3C–F). The TGFβ signaling pathway is well documented 
with a promoter of tumor progression and invasion32. Together, these two lincRNAs probably participate in the 
pathogenesis of breast cancer.
LincRNAs associated with breast cancer subtypes. We also investigated whether these 37 DE lin-
cRNAs exhibited expression difference across different breast cancer subtypes. We found three lincRNAs: 
GATA3-AS1 (ENSG00000197308), RP11-279F6 (ENSG00000245750) and AC017048 (ENSG00000224577), 
showed specifically high expression levels in ER-positive (ER+ ), compared to ER-negative (ER-) cancers and 
normal breast tissue samples (Fig. 4A). The specific expression alteration of these three lincRNAs in ER+ subtype 
was also validated in the replication stage. We also used the data of differentially expressed lincRNAs across four 
breast cancer subtypes (Luminal A, Lumnal B, Her2, and Basal-like) reported in Su et al. study30 to evaluate the 
subtype associations for these 37 lincRNAs. We found that the 22 (59.5%) lincRNAs (8 up-regulated lincRNAs 
and 14 down-regulated lincRNAs) were differentially expressed in at least one breast cancer subtype (Table S6). 
Three above reported lincRNAs over-expressed in the ER+ subtype (Fig. 4A) showed much higher expression 
levels in Luminal A and Lumnal B subtypes (enriched for ER+ ), relative to Her2, and Basal-like subtypes.
Further integrating two independent estrogen receptor alpha (ERα ) ChIP-seq dataset (each with two rep-
licates) in MCF-7 cancer cells, we observed the ERα binding sites in all three lincRNA loci (Fig. 4B–D). For 
example, an ERα DNA binding site was found near the transcriptional terminal region of the GATA3-AS1 based 
on the analysis of ERα ChIP-seq data (Fig. 4B). This binding region was further annotated as the active enhancer 
region using chromatin states in human mammary epithelial cells (HMECs). Similarly, this enhancer state was 
also observed in the other two lincRNAs (Fig. 4C,D). These results indicated that these three ER status associated 
lincRNAs may be regulated by ERα .
LincRNAs associated with breast cancer survival. We assessed the association of those 37 lincR-
NAs expression levels with breast cancer survival and found one candidate (RP5-1198O20 with Ensembl ID 
ENSG00000230615, Fig. 5). Patients with expression levels of lincRNA ENSG00000230615 higher than the 
median value (median FPKM value is 2.8) had worse survival rates than those women with expression levels less 
than the median value (median FPKM value is 0.5) (Fig. 5).
Discussion
In this study, we analyzed lincRNA transcriptome in over 1000 breast tissue samples. Two independent sequenc-
ing datasets consistently identified a set of lincRNAs deregulated in breast carcinogenesis. Importantly, the 
protein-coding genes neighboring these deregulated lincRNA loci also showed expression alternation in breast 
cancer tissues, implying the transcriptional concordance between lincRNAs loci and neighboring genomic 
regions in cancer development. The expression aberration of lincRNAs in breast cancer may be associated with 
the expression alteration of multiple TFs. Our work substantially extends the biological understanding of the 
lincRNA repertoire in the pathogenesis of breast cancer.
It should be noted that the aberrant expression of several lincRNAs previously identified in multiple cancers 
showed deregulation in the present study. For example, in both discovery and validation stages, expression levels 
of the MEG3 decreased in breast tumor samples, which is consistent with the proposed tumor suppressor role for 
MEG312,30. Another un-regulated lincRNA, GATA3-AS1 (Ensembl ID ENSG00000197308) was also identified in 
Ding et al. study33. Our in silico functional prediction (Table S5) indicated the GATA3-AS1 probably performs an 
immune response associated role in breast cancer progression. This result was supported by previous two stud-
ies29,34 showing that the GATA3-AS1 is highly expressed in T helper subsets. Spurlock et al. also speculated that 
the GATA3-AS1 might play a role in allergic or asthmatic responses34. In addition, this lincRNA was also reported 
to have a decreased expression level in brain, bladder and prostate cancers22. Another breast cancer survival 
associated lincRNA RP5-1198O20 (Ensembl ID ENSG00000230615) showed the up-regulation in both stages 
www.nature.com/scientificreports/
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of this study. Re-examining Gibb et al. integrated SAGE-seq findings22, we confirmed that this lincRNA also 
showed an increased expression in breast cancers. Another study about transcriptome analysis of aging identified 
the down-regulation of this lincRNA35. Further functional investigation of the lincRNA RP5-1198O20 in either 
carcinogenesis or aging would be interesting. In another example, our data showed the down-regulation of the 
miRNA-145 host gene (MIR145 with Ensembl ID ENSG00000269936) in breast cancer, consistent with previous 
reports in breast cancer36 and other cancer types37,38. However, several well-characterized lincRNAs12,22,23,39,40, 
including HOTAIR, H19, GAS5, PCA3, PVT1, were not investigated in this study. Those lncRNAs are not tran-
scribed from intergenic regions, belonging to either anti-sense or other types of long non-coding transcripts, 
according to the GENCODE (version17) annotation. That means these lncRNAs are difficult to distinguish from 
their host protein-coding genes using the typical RNA-seq technology. There are several lncRNAs with no polyA 
tails41,42 which are unmeasured in the current study as well. Therefore, more sophisticated methods, such as 
strand-specific and non-poly(A) tail RNA-seq technology, are required to distinguish anti-sense transcripts from 
protein-coding genes, and to comprehensively capture the lncRNA transcriptome.
Several lincRNAs show expression alteration in other cancers, including NEAT1 (Ensembl ID 
ENSG00000245532) down-regulated in retinoblastoma22, MALAT1 (Ensembl ID ENSG00000251562) 
Figure 4. Specific expression of lincRNAs in breast cancer subtypes. (A) Heatmap of three lincRNAs 
specifically over-expressed in ER+ breast cancer. Red and green represent 664 ER+ and 196 ER- cancer samples 
from TCGA, respectively. Black bar denotes 85 adjacent normal tissues. Distribution of DNA binding by ERα 
in three lincRNA genes, (B) GATA3-AS1 (Ensemble ID ENSG00000197308), (C) RP11-279F6 (Ensemble ID 
ENSG00000245750) and (D) AC017048 (Ensemble ID ENSG00000224577). The gray bars represent the DNA 
binding enrichment for the ERα in the MCF-7 cells. The track in the top for each lincRNA is the chromatin 
states from the chromHMM algorithm in the HMEC cell line. Chromatin states with bright red and light red, 
orange and yellow, blue, green and grey represent active promoter and weak promoter, strong enhancer and 
weak/poised enhancer, insulator, transcriptional region and heterochromatin/low signal, respectively.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:37821 | DOI: 10.1038/srep37821
up-regulated in lung and colorectal cancer43,44. However, these lincRNAs do not exhibit expression aberration 
in breast cancer. Likewise, the PCAT1 (Ensembl ID ENSG00000253438), a prostate-specific lincRNA regulating 
cell proliferation, shows over-expression in a subset of prostate cancers45. In our study, we almost did not detect 
the expression level of the PCAT1 in either breast normal or breast tumor samples. These results partially support 
the observation that many lincRNAs are expressed in a tissue- and cancer-type restricted manner, making them 
useful as prognostic markers12.
However, some limitations remain in this study. Firstly, no functional validations on these DE lincRNAs pre-
vent us draw the further conclusion about how the aberrant expression of lincRNAs contribute to tumorigenesis. 
Secondly, the relative small sample size and the unavailability of breast cancer subtype data in the replication 
stage also prevent us replicate the subtype-specific lincRNAs. Finally, due to the tumor heterogeneity and the cell 
mixture in tumor tissues, global comparison of gene expression profiles among breast tumor, adjacent and normal 
tissues is insufficient, particularly for lincRNAs whose expression patterns broadly show the cell- or tissue-type 
specificity. Thus, single-cell or sorted cell population based transcriptomic analysis46,47 will be favorable to deter-
mine these lincRNAs as robust biomarkers.
Conclusions
We identified a signature of lincRNA expression profile for breast cancer. Further functional surveys of these 
lincRNAs will be warranted to discover the biological mechanisms of lincRNA in breast cancer development and 
progression.
Materials and Methods
Discovery dataset. After approval, raw RNA-seq data (Level 1) of breast tumor tissues (N = 915) and adja-
cent normal breast tissues (N = 85) were acquired from the TCGA. Clinical data (Biotab format) for these 915 
breast invasive carcinoma (BRCA) were also acquired from the TCGA.
Replication dataset. Our replication study consisted of 50 breast cancer cases and 23 healthy controls. 
The patients were pathologically confirmed for primary breast cancer diagnosed at one of three hospitals in 
Indianapolis, Indiana, between 1998 and 2009: Indiana University Hospital, Wishard Hospital (now Eskenazi 
Hospital), and the Indiana University Simon Cancer Center (IUSCC). Controls were randomly selected from 
a pool of healthy women who donated normal breast tissues to the Susan G. Komen Tissue Bank between 2005 
and 2009, and were free of breast cancer at the time of donation. The participants completed a questionnaire on 
medical histories and health-related exposures at the time of donation. Controls were frequency matched to cases 
based on self-reported ancestry and age (within 5 years).
Breast tissue (untreated tumor or normal) biospecimens were collected from each case and control under 
standard operating procedures at IUSCC. All breast tissue samples were snap-frozen immediately after removal 
and stored in liquid nitrogen until processed, and were determined to be of high quality through histological and 
molecular quality control tests. Tumor samples were pathologically verified for high tumor content. Information 
concerning demographics, clinical data, and personal risk factors, including age and race, were either extracted from 
medical records (for cases) or obtained through the questionnaires completed by the participants (for controls).
Figure 5. Association of lincRNA expression levels with breast cancer survival. Kaplan-Meier survival plots 
for the lincRNA RP5-1198O20 (Ensemble ID ENSG00000230615). Two groups (higher and lower expression) 
are separated on the basis of the median expression level of lincRNAs across breast cancer patients.
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Total RNA was extracted from freshly frozen breast tissue samples using the Qiagen® miRNeasy Mini Kit. 
Construction of cDNA libraries and subsequent RNA sequencing of paired-end reads (2 × 50 nt reads) were per-
formed according to the standard Illumina protocol using the HiSeq2000 sequencing systems. The raw sequenc-
ing output was 25–35 million reads per sample.
Other dataset. The annotation data for known lincRNAs (n = 6,020) were extracted from the gencode.v17.
long_noncoding_RNAs.gtf.gz file from the GENCODE database. Other data used in this study include: human 
Refseq genes obtained from the NCBI database; protein-DNA interactions from ChIP-seq data in MCF-7 breast 
cancer cell lines downloaded from ENCODE project48; DNA binding by ERα using ChIP-seq in MCF-7 cells, 
and RNA-seq data across 14 breast cancer cell lines49,50 downloaded from the Gene Expression Omnibus (GEO) 
database51.
RNA-seq data processing and lincRNA annotation. In the discovery stage, for the 85 pair of matched 
breast tumor and normal tissues, mapped reads in BAM format (Level 1) were assembled with Cufflinks (v2.1.1)52. 
The lincRNA annotation was conducted by the following procedures: 1) we retained assembled transcripts whose 
genomic loci are overlapped or imbedded with known annotated lincRNAs; 2) we removed transcripts in length 
of < 200 nt; 3) we eliminated transcripts showing coding potential (score < 0.5) predicted with iSeeRNA program 
(version 1.2)53; 4) if two or more transcripts (isoforms) mapped to a lincRNA locus, we assigned the mean cov-
erage and expression value to that lincRNA. We applied the same procedures for the remaining RNA-seq data, 
except for publically accessible RNA-seq data that were processed as described elsewhere54. To reduce the noise 
caused by the lincRNA expression variability between samples, we plotted the calling rate (occurrence of lincRNA 
transcription based on Cufflinks FPKM ≥ 0.3) versus lincRNAs ranked by missing rate across 170 samples. As 
Ramskold et al. proposed55, this cutoff (FPKM ≥ 0.3) is an optimized threshold for detectable expression above 
background. Then, we set the calling rate ≥ 20% as a threshold to ensure high-confidence lincRNAs for further 
analyses.
For RNA-seq data in the replication stage, quality control (QC) filtering was first performed on raw RNA-seq 
data to remove adapter sequences and poor quality bases using the FastqMCF clipping algorithm. RNA-seq reads 
were then mapped by Bowtie v1.0.0, to GENCODE lncRNA reference (release 17) for lncRNA (including lin-
cRNA) annotations. Transcript abundances were quantified using NGSUtils. Samples were further filtered based 
on percentage of genes detected (less than 50%) and percentage of reads mapped to the reference (less than 25%). 
Extreme outliers were further identified and filtered from the dataset using principal component analysis (PCA). 
After these steps, a total of 7,450 lncRNAs retained and were used in further analyses.
ChIP-seq data processing. For ChIP-seq data from the ENCODE project, we directly downloaded files 
with called peaks for subsequent analyses. For two independent ERα ChIP-seq data whose processed peaks were 
unavailable, we downloaded the raw data in FASTQ format and conducted the peak calling as follows. Reads were 
mapped to the human reference genome (hg19) using Bowtie2 program56 in the default parameters. Aligned data 
were processed and converted into BAM files using SAMtools program57. Then, we used the MACS14 (version 
1.4.2) program58 to call peaks in 20 bp resolution. We visualized the results in the UCSC Genome Browser.
Differential expression of lincRNAs. The fragments per kilobase of exon per million fragments mapped 
(FPKM) values were calculated from the Cufflinks program to represent lincRNA expression levels. The differ-
ential expression of each lincRNA between breast tumor and adjacent normal tissues was defined as: fold change 
(FC) ≥ 2 with Benjamini-Hochberg (BH) adjusted P < 0.01 based on non-parametric Wilcoxon rank sum paired 
test.
Following the permutation-based method developed by Xie et al.59, we estimated the FDR in identifying lin-
cRNAs with differential expression. Briefly, FDR is estimated as = 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permutations were achieved by shuffling the tumor/normal samples in the lincRNA-sample matrix (584 lincR-
NAs and 170 samples).
For RNA-seq data in the replications stage, differential expression (DE) analyses were performed using edgeR 
v2.6.12, implemented in the Bioconductor package to identify differentially expressed lncRNAs between tumor 
and adjacent normal, as well as tumor and normal breast tissue. The trimmed mean of M-values (TMM) method 
was used to normalize the raw read counts. Biological coefficients of variation between the samples were esti-
mated using an empirical Bayes approach under the assumption that the data follows a negative binomial distri-
bution. Differential expression between tumor and adjacent normal or normal breast tissue was analyzed using 
a generalized linear model to regress lncRNA (expression on tissue type, adjusting for age, race, and sequencing 
batch). Statistical significance was defined as FDR p-value < 0.05 and a two-fold change (FC) of expression level 
between comparison of tumor and adjacent normal or normal breast tissue.
Construction of transcription factor and lincRNA network. We downloaded ChIP-seq peak files of 
26 transcription factors (TFs) in the MCF-7 breast cancer cells from the ENCODE project. A lincRNA bound by 
a TF was determined, if the TF binding peak is located within the region of 2 kb upstream of its transcription start 
site (TSS) to transcription end site (TES) of the lincRNA locus. Then, a lincRNA-TF bipartite network was con-
structed using the Cytoscape (v2.8.3) software60, where each node denotes a lincRNA or TF and each edge rep-
resents a lincRNA-TF interaction. The degree of each node in this bipartite network was calculated. We regarded 
the nodes representing TFs having ≥ 5 degrees as key TFs.
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Co-expression analysis. We used similar methods for lincRNA annotation to annotate Refseq protein- 
coding genes and calculate their FPKM values. The neighboring protein-coding genes were defined as the ones 
with the closest physical distance to known lincRNAs. We coupled lincRNA-encoding locus and neighboring 
protein-coding genes, and referred to it as a lincRNAs-mRNA pair. We further classified lincRNAs-mRNA pairs 
into three types, according to their transcriptional orientation: head-to-head (H2H), head-to-tail (H2T) and 
tail-to-tail (T2T). The linear relationship of log2-transformed fold change in a comparison of 85 paired samples 
for lincRNA-mRNA pairs was used to evaluate the coordinated changes.
We defined the non-neighboring genes as the ones over a 1 Mb physical distance from lincRNAs on both 
strands. We coupled them as non-neighboring lincRNAs-mRNA pairs. Similarly, we determined the coordinated 
changes for non-neighboring lincRNA/mRNA pairs. We repeated the analysis using randomly selected 1,000 
lincRNA-mRNA pairs (regardless of the distance) from the entire transcriptome data.
Functional prediction of lincRNAs. To predict biological functions for these DE lincRNAs, we calculated 
the correlation coefficients between DE lincRNAs and all Refseq protein-coding genes using the Spearman rank 
correlation analysis. We regarded the Spearman rank correlation coefficients calculated from randomly shuffling 
lincRNA/mRNA pairs (1000 times) as null distribution. Compared with the null distribution, we set a threshold 
for the Spearman rank correlation coefficient ≥ 0.4 (or ≤ − 0.4) (Figure S6) to reflect the strong co-expression 
between lincRNAs and Refseq genes in high confidence. On this basis, a set of Refseq genes passing this thresh-
old were regarded as the functional association to lincRNAs, and used for functional enrichment analysis using 
DAVID annotation61. GO terms with BH-adjusted P ≤ 0.05 served as functional enrichment for lincRNAs.
Survival analyses. Excluding participants with unknown survival information (n = 16), the remaining 899 
subjects were retained in survival analyses. We split patients into two groups (higher and lower expressions of 
lincRNA) based on the median level of lincRNA expression. The Kaplan-Meier curve and hazard ratio (HR) of 
higher versus lower expressed groups were generated in R (versions 2.15.0) using the survival package.
Ethical consent. Utilization of data was conducted in accordance with TCGA data access policies. Signed 
informed consent was obtained from each subject in the replication study. The study was approved by Indiana 
University institutional review board.
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